Neuroimaging Provides Insights into New Treatment Options for Alzheimers Disease: Investigators Report Findings in Special Issue of Behavioural Neurology

With about 35 million people around the world suffering from Alzheimer's disease (AD) by the year 2010 and an expectation that these numbers will double every twenty years with approximately 115 million cases by 2050, pressure on healthcare systems worldwide will be intense. In a special issue of the journal Behavioural Neurology, twelve contributions from an international group of researchers discuss imaging techniques that may contribute to early diagnosis and advancements in treatment for this devastating disease (see also Alzheimer Disease).

As life expectancy increases across the globe, the incidence of AD rises dramatically. Currently, AD care costs US Medicare and Medicaid and businesses over $148 billion dollars per year. With an aging population, these costs could potentially triple by 2050. With the prevalence of AD doubling with every decade of life after age 75, merely delaying the onset of AD by five years would produce a 50% decrease in the prevalence of disease.

According to Guest Editor Adam S. Fleisher, M.D., M.A.S., Associate Director of Brain Imaging at the Banner Alzheimer's Institute, "To effectively target prevention therapies at the pre-clinical stage of the disease, we must develop biomarkers which accurately predict future dementia. Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) offer great promise as biomarkers for identifying underlying structural, functional and disease specific pathology in AD, MCI and related disease processes."

In this volume, imaging experts present both reviews of the latest developments in this field as well as original work, supporting the conviction that neuroimaging will be of crucial importance in tackling this globally pervasive disease.

Behavioural Neurology: An International Journal with an Emphasis on Lesion and Imaging Studies that Explore Abnormal Human Cognition and Behaviour

Special Issue: Alzheimer's Disease and Mild Cognitive Impairment: New Insights from Imaging, Volume 21, Issues 1-2

Published by IOS Press

(Also published as a book edition: ISBN 978-1-60750-066-7, approx 140 pages, softcover, €110/$160)

Guest Editor: Adam S. Fleisher

Table of Contents:

Structural neuroimaging in the detection and prognosis of pre-clinical and early AD

Christine Fennema-Notestine, Linda K. McEvoy, Donald J. Hagler, Jr., Mark W. Jacobson, Anders M. Dale and the Alzheimer's Disease Neuroimaging Initiative

A comparative analysis of structural brain MRI in the diagnosis of Alzheimer's disease

Jason Appel, Elizabeth Potter, Qian Shen, Gustavo Pantol, Maria T. Greig, David Loewenstein and Ranjan Duara

Fully-automated volumetric MRI with normative ranges: Translation to clinical practice

J.B. Brewer

Cognitive phenotypes, brain morphometry and the detection of cognitive decline in preclinical AD

Mark W. Jacobson, Linda K. McEvoy, Anders Dale and Christine Fennema-Notestine

Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment

G.T. Stebbins and C.M. Murphy

Changes in parahippocampal white matter integrity in amnestic mild cognitive impairment: A diffusion tensor imaging study

E.J. Rogalski, C.M. Murphy, L. deToledo-Morrell, R.C. Shah, M.E. Moseley, R. Bammer and G.T. Stebbins

Large-scale functional brain network abnormalities in Alzheimer's disease: Insights from functional neuroimaging

Bradford C. Dickerson and Reisa A. Sperling

Functional MRI assessment of task-induced deactivation of the default mode network in Alzheimer's disease and at-risk older individuals

Maija Pihlajamaki and Reias A. Sperling

Pinpointing synaptic loss caused by Alzheimer's disease with fMRI

Adam M. Brickman, Scott A. Small and Adam Fleisher

Diagnosis of Alzheimer's disease with [18F]PET in mild and asymptomatic stages

Alexander Drzezga

Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo

G.D. Rabinovici and W.J. Jagust

Applications of neuroimaging to disease-modification trials in Alzheimer's disease

Adam S. Fleisher, Michael Donohue, Kewei Chen, James B. Brewer, Paul S. Aisen and the Alzheimer's Disease Neuroimaging Initiative

# # #

Please contact Esther Mateike at IOS Press, Tel: +31 20 688 3355, This e-mail address is being protected from spambots. You need JavaScript enabled to view it to request articles of interest. Journalists wishing to interview Dr. Adam S. Fleisher should contact him at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

About Behavioural Neurology

Behavioural Neurology publishes original experimental papers and case reports dealing with disordered human behavior and exceptional animal studies that have direct implications for understanding human behavior or neural mechanisms of cognition. These embrace the field of cognitive neurology, biological psychiatry, neuropsychology, rehabilitation, and cognitive neuroscience. The emphasis of the approach is on lesion and imaging studies that explore abnormal human cognition and behavior. The journal embraces matters of interest to clinicians, such as behavioral neurologists and neuropsychiatrists, and cognitive neuroscientists, neuropsychologists, neuropathologists, neurochemists, therapists, psychopharmacologists and metabolic scientists with a special interest in human neurological disorders. All papers are refereed.

About IOS Press

Commencing its publishing activities in 1987, IOS Press (www.iospress.nl) serves the information needs of scientific and medical communities worldwide. IOS Press now (co)publishes over 100 international journals and about 130 book titles each year on subjects ranging from computer sciences and mathematics to medicine and the natural sciences. IOS Press continues its rapid growth, embracing new technologies for the timely dissemination of information. All journals are available electronically and an e-book platform was launched in 2005.

Headquartered in Amsterdam with satellite offices in the USA, Germany, India and China, IOS Press has established several strategic co-publishing initiatives. Notable acquisitions included Delft University Press in 2005 and Millpress Science Publishers in 2008.

Contacts:

Guest Editor:

Adam S. Fleisher, M.D., M.A.S.

Associate Director of Brain Imaging

Banner Alzheimer's Institute

Medical Director, Alzheimer's Disease Cooperative Study

Assistant Professor, Department of Neurosciences

University of California, San Diego

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Esther Mateike

IOS Press

Tel: +31 20 688 3355

Fax: +31 20 620 3419

This e-mail address is being protected from spambots. You need JavaScript enabled to view it